Literature DB >> 33634224

Takotsubo syndrome following MitraClip procedure.

Takehiro Nomura1, Yoshiko Munehisa1, Masaki Nakashima1, Takashi Matsumoto1.   

Abstract

Entities:  

Year:  2020        PMID: 33634224      PMCID: PMC7891285          DOI: 10.1093/ehjcr/ytaa384

Source DB:  PubMed          Journal:  Eur Heart J Case Rep        ISSN: 2514-2119


× No keyword cloud information.
An 87-year-old man underwent a successful MitraClip (Abbott Vascular, Santa Clara, CA, USA) procedure for severe mitral regurgitation (MR) due to P3 prolapse with general anaesthesia and transoesophageal echocardiography guidance. The next morning, he complained of chest pain. Transthoracic echocardiography (TTE) demonstrated new severe apical akinesis without worsening of the MR (). Angiography revealed akinesis of the apex of the left ventricle with no coronary artery obstruction (Video 1), consistent with the diagnosis of takotsubo syndrome. The subsequent clinical course was uneventful, without elevation of cardiac enzymes (maximum creatine kinase 112 U/L). On postoperative day 6, TTE demonstrated normalization of the left ventricular apical wall motion, and the patient was discharged home. Left ventricular angiography. The figure shows left ventricular angiography in diastole (A) and systole (B). It reveals akinesis of the apex of the left ventricle with concomitant basal hyperkinesis. The onset of takotsubo cardiomyopathy is often proceeded by emotional or physical stress including open-heart surgery. Although the supporting evidence is limited, catecholamine-mediated multivessel epicardial spasm, microvascular coronary spasm, or possible direct catecholamine-mediated myocyte injury has been reported as possible pathophysiological mechanisms. MitraClip procedure is less invasive than open-heart surgery. However, this case demonstrates that it can nonetheless precipitate the onset of stress-induced takotsubo syndrome. Furthermore, a recent study has revealed that, in addition to emotional factors, takotsubo syndrome can also be triggered by physical factors, which was related to worse short- and long-term prognosis. Therefore, we should be aware of takotsubo syndrome as a potential complication of MitraClip procedure. Consent: The author/s confirm that written consent for submission and publication of this case report including image(s) and associated text has been obtained from the patient in line with COPE guidance. Conflict of interest: none declared.
  4 in total

Review 1.  Apical ballooning syndrome or takotsubo cardiomyopathy: a systematic review.

Authors:  Monica Gianni; Francesco Dentali; Anna Maria Grandi; Glen Sumner; Rajesh Hiralal; Eva Lonn
Journal:  Eur Heart J       Date:  2006-05-23       Impact factor: 29.983

Review 2.  Takotsubo's syndrome after mitral valve repair and rescue with extracorporeal membrane oxygenation.

Authors:  Stephanie Li; Michael M Koerner; Aly El-Banayosy; Behzad Soleimani; Walter E Pae; Urs A Leuenberger
Journal:  Ann Thorac Surg       Date:  2014-05       Impact factor: 4.330

3.  Percutaneous repair or surgery for mitral regurgitation.

Authors:  Ted Feldman; Elyse Foster; Donald D Glower; Donald G Glower; Saibal Kar; Michael J Rinaldi; Peter S Fail; Richard W Smalling; Robert Siegel; Geoffrey A Rose; Eric Engeron; Catalin Loghin; Alfredo Trento; Eric R Skipper; Tommy Fudge; George V Letsou; Joseph M Massaro; Laura Mauri
Journal:  N Engl J Med       Date:  2011-04-04       Impact factor: 91.245

4.  Short- and Long-Term Prognosis of Patients With Takotsubo Syndrome Based on Different Triggers: Importance of the Physical Nature.

Authors:  Aitor Uribarri; Iván J Núñez-Gil; D Aritza Conty; Oscar Vedia; Manuel Almendro-Delia; Albert Duran Cambra; Agustin C Martin-Garcia; Marisa Barrionuevo-Sánchez; Manuel Martínez-Sellés; Sergio Raposeiras-Roubín; Marta Guillén; Jose Maria Garcia Acuña; Lucía Matute-Blanco; José A Linares Vicente; Alejandro Sánchez Grande Flecha; Mireia Andrés; Alberto Pérez-Castellanos; Javier Lopez-Pais
Journal:  J Am Heart Assoc       Date:  2019-12-13       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.